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Life-cycle assessment (LCA) is an environmental assessment tool that quantifies the envi-
ronmental impact associated with a product or a process (e.g., water consumption, energy
requirements, and solid waste generation). While LCA is a standard approach in many com-
mercial industries, its application has not been exploited widely in the bioprocessing sector.
To contribute toward the design of more cost-efficient, robust and environmentally-friendly
manufacturing process for monoclonal antibodies (mAbs), a framework consisting of an LCA
and economic analysis combined with a sensitivity analysis of manufacturing process param-
eters and a production scale-up study is presented. The efficiency of the framework is dem-
onstrated using a comparative study of the two most commonly used upstream configurations
for mAb manufacture, namely fed-batch (FB) and perfusion-based processes. Results
obtained by the framework are presented using a range of visualization tools, and indicate
that a standard perfusion process (with a pooling duration of 4 days) has similar cost of
goods than a FB process but a larger environmental footprint because it consumed 35%
more water, demanded 17% more energy, and emitted 17% more CO2 than the FB process.
Water consumption was the most important impact category, especially when scaling-up the
processes, as energy was required to produce process water and water-for-injection, while
CO2 was emitted from energy generation. The sensitivity analysis revealed that the perfusion
process can be made more environmentally-friendly than the FB process if the pooling dura-
tion is extended to 8 days. VC 2016 The Authors Biotechnology Progress published by Wiley
Periodicals, Inc. on behalf of American Institute of Chemical Engineers. 000:000–000, 2016
Keywords: life-cycle assessment (LCA), monoclonal antibody, environmental assessment,
sustainability, decision-making
Introduction
The design of a manufacturing process for biopharmaceuti-
cals, such as monoclonal antibodies (mAbs), or any other
commercial product is based on various criteria, such as capi-
tal investment, operating costs, process reliability and safety,
and environmental impact.1 While research on the economics
of biomanufacturing processes has become popular in the last
10 years,2–6 there is little research and insight into the envi-
ronmental impacts of adopting particular biomanufacturing
processes and different biomanufacturing technologies. Life-
cycle assessment (LCA)7,8 is a systematic method that focuses
on describing the environmental consequences of each ele-
ment in a process but has not been used widely within the
bioprocessing sector. The goal of this work is to propose an
LCA-based framework to contribute toward designing more
cost-efficient, robust and environmentally-friendly manufactur-
ing processes for mAbs, which are arguably the highest sell-
ing class of biopharmaceuticals with a sales value of
approximately $24.6 billion in 2012 in the United States.9
Currently, the large-scale production of mAbs is based on
production systems that use recombinant mammalian cells.10
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Fed-batch (FB) bioreactors have become the default plat-
form technology for large-scale production of mAb due to
their ease of scalability (up to 20,000 L), robustness, and
high volumetric productivity.11 In contrast to a FB bioreac-
tor, a perfusion bioreactor operates continuously by feeding
and withdrawing the culture media while retaining cells
within the bioreactor.12,13 The operability of a new piece of
equipment or a process needs to be weighed against the
resulting economic advantages and environmental burdens.
While there is literature emerging on the economic impact
of different bioreactor types,3,6 the environmental burdens
remain rather unexplored. To gain a better understanding of
the trade-offs between the economic and environmental
impact of FB and perfusion-based manufacturing processes,
we present here an LCA-based framework comprising an
LCA modeling software (GaBi) and an industry standard
bioprocess model (BioSolve). The framework has the ability
to assess a specific manufacturing process as well as high-
light the impact of uncertainties in process parameters and
production scale-up on economic and environmental metrics.
Related research
Previous work on evaluating the environmental impact of
biopharmaceutical manufacturing was not based on LCA but
largely on two metrics, namely the process mass intensity
(PMI) or the E-factor.3,14,15 The PMI15 is calculated by
dividing the total input (kg) of starting materials, reagents,
solvents and process water by the output (kg) product, while
the E-factor16 is defined by the ratio of the mass of waste
per unit of product. Traditionally, the PMI and E-factor do
not assess water consumption of non-process related steps
nor the cumulative energy demand.17 The American Chemi-
cal Society Green Chemistry InstituteVR (ACS GCI) Pharma-
ceutical Roundtable selected PMI to benchmark processes
across the pharmaceutical industry.15 Ho et al.14 used the E-
factor to assess the impact of therapeutic biologics in gener-
al. Similar to this study, Pollock et al.3 compared FB and
perfusion-based processes using the E-factor. Pollock et al.
computed E-factor values for the water consumption of pro-
cess and non-process related steps but did not evaluate
aspects related to energy consumption and CO2 emissions,
which contribute significantly to the overall environmental
assessment of a process as will be demonstrated later.
Compared with the PMI and E-factor, LCA is a more
comprehensive environmental assessment tool15 and accounts
for the environmental impact of the individual production
stages ranging from raw material extraction to equipment
disposal. Unlike the PMI and E-factor, LCA allows various
additional impact categories to be evaluated, such as toxico-
logical impacts, global warming potential, acidification, and
loss of biodiversity. Only a few LCA studies have been con-
ducted to date with all focusing on the environmental assess-
ment of a traditional fixed-in-place stainless-steel facility
versus a facility that relies on single-use equipment.18–21
Arguably, the first streamlined LCA study within the bio-
pharma sector was conducted by GE Healthcare in collabora-
tion with Yale University in 2009 based on a WAVE 500
single-use bioreactor.19 Following this study, GE Healthcare
initiated a major LCA study in collaboration with BioPharm
Services Ltd and GE’s Global Research Ecoassessment Cen-
ter of Excellence.20 The goal of the study was to compare
the use of single-use versus traditional durable process tech-
nologies at levels of 100, 500, and 200 L scales. The results
indicated that a single-use process train exhibited lower envi-
ronmental impact compared with the traditional fixed-in-
place process train in each environmental impact category
(17 in total) studied. This observation was primarily due to
the reduced need for energy and water intensive process
steps that are required for traditional fixed-in-place equip-
ment. This study will show that, in the context of FB and
perfusion-based processes, there are certain conditions
(e.g., as a function of the perfusion pool duration) at which
“environmental friendliness” can switch from one process
platform to another. Finally, the most recent work on LCA
within the biopharmaceutical industry provides methodo-
logical guidelines on the application of LCA in the design
of environmentally-friendly biomanufacturing processes,
and also proposes a decision-support LCA tool to achieve
this.22
The LCA-based framework proposed in this study follows
established guidelines,22 and derives process costs and facili-
ty data using models developed by Biopharm Services Ltd,
BioSolve, which was already used in Ref. 20. The applica-
tion of the framework to the environmental assessment of
FB and perfusion-based bioprocesses is complementary to
previous work that focused solely on assessing single-use
and traditional multi-use bioprocessing systems.
Methodology
This first part of this section introduces briefly the steps
that constitute LCA, and describes the system boundary con-
sidered in this work to validate the environmental impact of
two commonly used mAb manufacturing technologies.
Life-cycle assessment
Applying the concept of life-cycle thinking avoids shifting
the environmental burden from one production phase to
another. This is achieved through the implementation of four
stages:23 First, the purpose of the study, the system bound-
ary, and the type of information needed are defined in the
goal and scope definition stage. This is followed by a life-
cycle inventory (LCI) analysis, where mass and energy bal-
ances across the system boundaries are quantified. Conse-
quently, the data from the LCI analysis is used to evaluate
the different environmental impacts within the life-cycle
impact assessment. Finally, the results are analyzed and nec-
essary process modifications suggested in the interpretation
stage. Arguably, while water consumption, largely related to
clean-in-place (CIP) and steam-in-place (SIP) systems, repre-
sents a major environmental burden, biopharmaceutical
manufacturing can impact the environment in various other
ways too including (liquid and solid) waste generation, ener-
gy consumption, and greenhouse gas (GHG) emission.24 In
particular, waste generation can pose a great environmental
challenge as plastic waste is generally not recycled due to its
multicomponent nature.25 Current options to dispose the
waste include landfill, incineration, and pyrolysis.26 Simulat-
ing and understanding the impact of these options in the con-
text of biopharmaceutical manufacturing is a major objective
of this work.
Energy consumption is also associated with a large foot-
print in the biopharma sector due to the necessity to main-
tain identical ambient operating conditions so to ensure
consistent product quality. In fact, the energy dedicated to a
heating, ventilation, and air conditioning (HVAC) system is
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estimated to constitute 65% of the total energy requirement
of a pharmaceutical plant.51 Other energy-intense operations
in a biopharmaceutical plant include the production of puri-
fied water (PW) and water-for-injection (WFI), equipment
cleaning and sterilization, mass and heat transfer arising in
upstream processes, and fluid transport and mixing present in
downstream processes.14 An increasing awareness and inter-
est of the industry in climate change is also now reflected in
environmental concerns over GHG emission levels.21 Typical
sources of GHG emissions in a biopharmaceutical plant
include electricity and steam generation, fermentation, and
transportation of facility workers.
While previous LCA studies compared the impact of single-
use versus multi-use bioprocess systems,18–21 this current study
goes a step further and demonstrates how LCA can be linked
to a bioprocess simulation model to select a manufacturing
strategy based on either FB or perfusion bioreactors with the
goal to minimize water consumption, levels of solid waste gen-
eration, energy requirement, and CO2 emissions.
The LCA system boundary of the cradle-to-gate approach
adopted in this study encompasses the supply-chain phase
and the use phase, and is summarized in Figure 1. Typically,
the supply-chain phase contains three primary processes:
equipment fabrication, consumables manufacture, and
reagent preparation. The first two processes are relevant
when comparing single versus multi-use bioprocess systems
as consumable components in the manufacturing process can
have a significant effect on the overall environmental impact.
However, since this LCA study focuses on systems that use
stainless-steel equipment with little solid waste generation
upfront, it is sufficient to account only for the environmental
impact caused by the reagent preparation process (hence
equipment and consumable manufacture was excluded from
this study as indicated in Figure 1). The use phase contains
the individual unit operations within a mAb manufacturing
process, and the management of solid and liquid wastes.*
FB versus perfusion-based mAb manufacturing processes
There are fundamental differences in the working princi-
ples of the two manufacturing processes considered in this
study, FB and perfusion-based processes, driven by the bio-
reactor type. In a FB bioreactor, the product remains in the
bioreactor until the end of the run, while a perfusion bioreac-
tor operates continuously by feeding and withdrawing the
culture media while retaining cells within the bioreactor. The
pool duration specifies the number of days for which harvest
is collected before it is sent for further processing. A typical
perfusion bioreactor can operate up to 601 days before the
run is terminated due to, for example, filter clogging, reduc-
tion of viable cells, and culture age.27 The size of a perfu-
sion bioreactor can reach up to 2,000 L with scalability
being limited by the robustness of the cell-retention system.
Generally, a perfusion bioreactor operates at a lower mAb
titer than a FB bioreactor. However, a perfusion bioreactor
has the ability to process unstable products and cultivate
cells at a cell density that is 100 times higher than achieved
with a FB bioreactor, allowing for the use of smaller
Figure 1. Summary of the cradle-to-gate system boundary based on the perfusion process. The operations included a section of the
supply-chain phase and the use phase. The centrifugation step, highlighted in the gray box, was considered in a batch-based
process but not in the perfusion-based process. BioSolve simulated the manufacturing process (indicated by the dashed line
in the use phase), and GABI computed the solid waste transportation and treatment (indicated by the dotted line in the use
phase). The energy requirements of the supply-chain phase were calculated using BioSolve and a facility area classification
approach. Components indicated by an asterisk (*) were excluded from the study.
*Note, a perfusion-based process does not require a centrifugation step dur-
ing the clarification stage since cells are retained in the perfusion bioreactor.
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bioreactors. Although, currently, perfusion mode is still per-
ceived as complex and difficult to operate,28 recent techno-
logical advances in the bioprocessing sector, related
particularly to single-use bioreactors and their linkage with
novel cell-retention systems, are expected to increase the oper-
ability and popularity of perfusion-based bioreactors.29–31
Constructing the mass balance model
The study assumed the production of a functional unit of
28 kg-mAb per year. This was calculated based on the
amount of Avastin required for a 5% market penetration to
treat lung cancer in the United Kingdom (please refer to
Appendix A for a justification and calculation of this produc-
tion output). To generalize our LCA study, the impact of
production scale-up to outputs greater than 28 kg-mAb per
year was investigated too.
Details related to mAb manufacture were obtained from
literature and process simulations using BioSolve, an indus-
try standard bioprocess model from BioPharm Services
(Chesham, United Kingdom). The simulation results provid-
ed facility data, such as equipment sizing, number of media
and buffer containers, Cost of Goods per gram (COGS/g) of
mAb, the equipment floor area, and the consumption of PW)
and WFI. This data constitutes a mass balance model, which
was the foundation for calculating system parameters and
quantifying different environmental impacts. Table 1 summa-
rizes the key assumptions used in the bioprocess simulation
(the remaining process parameter settings as used by Bio-
Solve are provided in Appendix B).
To meet a production target of 28 kg per annum we have
assumed typical titers for a FB (5g/L) and perfusion process
(2g/L) achieved in a manufacturing setup. The lag phase and
production bioreactor duration are set to standard values of 5
days and 12 days (FB)/30 days (perfusion), respectively.32
Typical pool durations can range from 2 to 7 days,28 and, in
general, the pool duration is chosen based on protein stabili-
ty and downstream capabilities. This study has chosen a
commonly reported duration of 4 days as the base case. For
industrial cell lines, perfusion rates of 0.5–2 VVD (volume-
of-fresh-medium/working-reactor-volume/day) have been
reported.33 Volume and number of bioreactor runs per year
were computed by BioSolve based on other provided param-
eters. Note that the perfusion-based process has a slightly
higher DSP yield than the FB-based process as it does not
involve a centrifugation step, and also yields more than
double the number of batches (as the pooling strategy
adopted leads to more frequent downstream runs). We are
aware that manufacturing processes can vary significantly
from the base case defined in Table 1. Thus, to investigate if
our conclusions are valid for a wider range of processes and
scales, we will carry out a sensitivity analysis on the process
parameters and production scale-up study. Ultimately, the
insights gained allow trade-offs between the two process
types to be identified and opportunities for process improve-
ments pinpointed.
We want to point out that although BioSolve was used to
calculate the annual water consumption of the manufacturing
facility, we believe that the consumption of a perfusion process
was overestimated because BioSolve assumed the upstream
stage was cleaned as frequently as the downstream stages.
Realistically, the seed and production bioreactors are cleaned
once every perfusion run and not after every purification run.
Consequently, while the upstream water consumption was
computed using BioSolve, the downstream water consumption
was calculated by multiplying the water consumption of a sin-
gle downstream run (which was computed by BioSolve) by the
number of downstream runs per run.
Constructing the energy balance model
A detailed energy balance scheme was beyond the capa-
bilities of BioSolve. Hence, we developed our own model
for this study based on literature data and vendor discussions
(Appendix C provides the key assumptions for constructing
the energy balance model). BioSolve provided crucial inputs
to the energy balance model such as water usage, production
runtime, and facility floor area. These parameters were
linked with our energy model capture energy usage related
to manufacturing operations, HVAC, water production,
reagent preparation, lighting, and waste management.
The energy required to operate each unit operation in the
mAb manufacturing process was calculated by multiplying the
equipment power input by the operating duration per year,
while the energy to operate the HVAC system was calculated
based on the floor area (as done in similar form in Ref. 21).
BioSolve provided both the total floor area for each area classi-
fication and the equipment operating duration per year. Table 2
shows the average energy consumption for each area classifica-
tion. The grades refer to different clean room types as required
for different tasks in the manufacturing process (please refer to
Refs 21,34 for a detailed explanation of the grades).
Evaluating solid waste management
This study investigated the environmental impact of three
solid waste treatment options: landfill, incineration, and
pyrolysis. The analysis of landfill and incineration was per-
formed using the GaBi software package35 with the GaBi
bundled professional database36 serving as the principal data
source. The GaBi software package is an established LCA
Table 1. Overview of Process Details Assumed for a FB and
Perfusion-Based mAb Manufacturing Process
Technical Properties
FB
Process
Perfusion
Process
Volume (L) 375 47
Titer (g-mAb/L) 5 2
Number of production bioreactor
runs per year
21 9
Production bioreactor
duration (days)
12 30
Pool duration (days) – 4
Lag phase (days) – 5
Perfusion rate (VVD) – 2
Overall downstream process yield 72% 76%
Number of batches
(or downstream runs) per year
21 53
Note. The properties pool duration, lag phase, and perfusion rate are
relevant to the perfusion process only.
Table 2. HVAC Energy Consumption for Each Class of Facility
Space
Area Classification (grade)
Average Energy Consumption
per Floor Area (kWh/m2)
B 854
C 237
D 119
U 47.0
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modeling software to quantify environmental impacts and has
been used widely in various industries, such as wine produc-
tion,37 wood panel industry,38 and power systems,39 to name
a few. Its application in the biopharma industry is still rare
(see e.g., Refs 19–21) but is expected to increase in populari-
ty significantly as the industry matures. Plastics represent the
major part of the solid waste generated by the manufacture of
mAb, and provide the driving multiplying factors in the esti-
mation of water consumption, energy requirements, and CO2
emission levels of the landfill and incineration processes. The
GaBi database does not contain data for the third treatment
option, pyrolysis. Discussions with industrial partners, includ-
ing Royal Dahlman (http://www.royaldahlman.com/), allowed
us to make reasonable assumptions about the performance of
pyrolysis. Table 3 summarizes the multiplying factors for all
three waste treatment options.†
Results and Discussion
Which process is generally more environmentally-friendly
and/or economical?
Table 4 summarizes the crucial environmental impact met-
rics—water consumption, solid waste generation, energy
consumption, and CO2 emission levels—and COGS/g for a
FB and perfusion-based process based on a functional unit
of 28 kg-mAb production per year. From Table 4 it is appar-
ent that a FB process is significantly more environmentally-
friendly than a perfusion-based process, while having only
slightly higher COGS/g. Note, the level of CO2 emission is a
function of the energy requirement (the interested reader is
referred to Ref. 40 for more details on this relationship)
causing both metrics to be proportional to each other. The
results are also in alignment with those reported by Pollock
et al.,3 though that study did not evaluate levels of energy
consumption and CO2 emissions.
To put the results into context with the UK domestic con-
sumption,41–43 a perfusion-based process consumed per year
an equal amount of water as 28 people, required an equiva-
lent amount of energy as around 100 households, and gener-
ated a little more solid waste than a single person would.
The following sections analyze the individual environmental
impact categories in more detail.
What are the key drivers for water consumption?
Water consumption varied across the upstream and down-
stream stages of a manufacturing process as can also be
observed from Figure 2. Interestingly, while the FB-based
process consumes less water overall, for upstream activities,
it consumes around double the amount of water than a
perfusion-based process (204 versus 407 tonnes of water/
year). This result may seem non-intuitive because the perfu-
sion bioreactor requires a constant input of fresh media and
thus one could expect the consumption for upstream activi-
ties to be higher. The explanation for this observation is that
a FB-based process undergoes cleaning after each batch. In
the presence of many batches (e.g., during commercial man-
ufacture stage or blockbuster drug) this turns out to consume
more water than maintaining a continuous perfusion-based
process that needs occasional cleaning only (21 cleans for
FB versus 9 cleans for perfusion, as can be seen in Table 1).
While the perfusion-based process consumes less water for
upstream activities, the water demand is almost double for
downstream activities (1290 versus 690 tonnes of water/
year). This is due to the fact that the perfusion-based process
operates its downstream process more than twice as frequent-
ly compared with a FB process leading to significantly
Table 3. Environmental Multiplying Factors of Three Solid Waste
Treatment Options, Landfill, Incineration, and Pyrolysis, Commonly
Used in the Biopharmaceutical Industry
Environmental Impact Type Landfill Incineration Pyrolysis
Water consumption factor
(kg-water/kg-waste)
40 7 7
Energy consumption
factor (MJ/kg-waste)
1 27 23
CO2-eq emission
(kg-CO2eq/kg-waste)
1 2 1
Table 4. Environmental Impact Metrics and COGS/g for a FB and
Perfusion-Based Process Based on 28 kg/Year of mAb
Process Performance
Metric FB Perfusion
Relative
Difference
Between FB
and Perfusion
Water consumption
(kg/year) 3 106
1.1 1.5 35.1%
Solid waste
(kg/year) 3 103
0.7 1.3 93.1%
Energy requirement
(MJ/year) 3 106
1.3 1.5 16.7%
CO2 emission
(kg/year) 3 106
0.17 0.20 17.4%
COGS/g (USD/g) 494 504 2.0%
Figure 2. Comparison of the overall water consumption of a
FB and perfusion-based process. Percent contribu-
tions are shown for different process activities
including chromatography ( ), production bioreac-
tor ( ), seed bioreactors ( ), cleaning of buffer prep-
aration / hold ( ), cleaning of media preparation /
hold ( ), and other unit operations ( ). For both
processes, the supply-chain and use phase comprised
46% and 54% of the total water consumption,
respectively. Basis for both cases is 28 kg-mAb/year.
†The input data to GaBi consists of the environmental multiplying factors as
specified in Table 3, and the average distance from the manufacturing plant
to the waste yard, which was set to 25 km, a value we obtained from discus-
sions with industrial partners.
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higher CIP and SIP costs, which make up more than 85% of
the total water consumption.
What are the key drivers for energy requirements?
Figure 3 shows the energy usage of FB and perfusion-based
processes for different manufacturing activities. It can be seen
that water production, which includes the production of PW
and WFI, and liquid waste treatment are the most energy inten-
sive steps, accounting for approximately 50% and 20% of the
overall energy demand, respectively. This means there is a pos-
itive correlation between water and energy usage, which is also
reflected in Table 4 with the FB-based process being more eco-
nomical in terms of both energy and water usage.
Figure 3 highlights also that the production bioreactor is
the most energy intensive unit operation accounting for
approximately 90% of the total energy requirement among
all the unit operations. This is due to the long running time
of a bioreactor and the complex setup investing energy in
temperature control, agitation, and gas sparging. By compari-
son, a modest amount of energy is invested in fluid transport
and mixing in other unit operations. The FB process con-
sumed more energy in its “other unit operations” due to the
need for large seed bioreactors.
It is worth noting that the HVAC system contributed
around 5% to the overall energy demand but that this contri-
bution could have been significantly greater if the energy-
balance model accounted for geographical-dependent factors
too (e.g., temperature control). HVAC energy requirements
of up to 4,000 kWh/m2 (which is more than 10-fold higher
than the consumption reported in this study)44 and contribu-
tions of up to 50% to the overall energy demand14 have
been reported in the literature. However, since the energy
requirements for the HVAC systems for a FB and perfusion-
based process differed by only 1% and did not depend heavi-
ly on the process being used (but rather on the geographical
factors), a larger energy requirement of the HVAC systems
is not expected to impact the ranking of the two processes in
terms of energy and water usage.
What are the key drivers for solid waste generation?
Figure 4 shows the key unit operations contributing to solid
waste generation for a FB and perfusion-based process. It can
be seen that the composition of solid wastes were similar for
both manufacturing processes with the top three components
being attributed to: (i) the three chromatography steps (50%
of total waste with 6–24% being resin waste and 76–94% fil-
ters), (ii) viral filtration (20% of total waste), and (iii)
upstream activities (<10% of total waste). Consequently,
since a perfusion-based process performs more (chromato-
graphic) downstream runs per year than a FB-based process,
it generated also more downstream-related waste (1.2 versus
0.6 tonnes). On the other hand, a perfusion-based process is
more economical on the upstream side (20% less waste than
a FB-based process) as it requires fewer upstream runs.
Figure 5 shows the water consumption (Figure 5a), energy
requirement (Figure 5b), and CO2 emission (Figure 5c) associat-
ed with the three waste treatment options, incineration, pyroly-
sis, and landfill. The options of incineration and pyrolysis
consumed five-times less water than landfill, and were able to
generate net energy that could be recycled back to supply the
manufacturing process (hence the negative energy input).‡ Incin-
eration generated most energy but it also emitted most CO2
because of the combustion process involved in this waste treat-
ment option. In summary, pyrolysis seems to strike the best bal-
ance between environmental impact and the potential to recycle
energy, while landfill performs poorly in terms of both aspects.
However, in contrast to the environmental impact generat-
ed by the manufacturing process per se, waste treatment rep-
resents only a tiny fraction (maximum 3% across the two
processes, FB versus perfusion, and impact categories). The
Figure 3. Comparison of the total energy requirement of FB
and perfusion processes. Percent contributions are
shown for different process activities including buff-
er & media preparation ( ), water production ( ),
liquid waste treatment ( ), production bioreactor
( ), HVAC ( ), and other unit operations ( ). For
the FB process, the supply-chain and use phase com-
prised 45% and 55% of the energy requirement,
respectively. For the perfusion-based process, the
supply-chain and use phase comprised 37% and
63% of the energy requirement, respectively. Basis
for both cases is 28 kg-mAb/year.
Figure 4. Comparison of the total solid waste generated by a
FB and perfusion process. Percent contributions are
shown for key process activities including upstream
( ), chromatography ( ), viral filtration ( ), and
other unit operations ( ). Waste was generated by
the supply-chain phase only. Basis for both cases is
28 kg-mAb/year.
‡In principal, the landfill process could generate energy too by collecting
methane gas obtained as a by-product from anaerobic digestion. However,
since non-biodegradable plastics do not readily decompose, they do not
generate methane gas.
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impact is also rather little compared with domestic usage:
for example, the water consumption of the landfill option is sim-
ilar to the annual water usage of a single person, and the CO2
emission associated with the incineration option is less than the
annual amount emitted by a single passenger vehicle.45
What are the key drivers for COGS/g?
Although the COGS/g of the FB and perfusion-based pro-
cess were similar ($494 versus $504 as can be seen from Table
4), there is a difference in the cost breakdown: The perfusion-
based process has a lower capital cost (57% versus 48%) due
to smaller pieces of equipment being deployed, especially a
smaller production bioreactor. However, this comes at the
expense of higher material, consumable, and labor costs since
the perfusion-based process employs more downstream runs
per year. In other words, a perfusion-based process is associat-
ed with a lower capital investment but higher variable costs,
which is a setup suitable for manufacturing drugs with uncer-
tain demand forecast as might be the case during clinical trials.
How sensitive is the environmental impact and COGS/g to
process parameter changes?
The results above were obtained using a fixed set of pro-
cess parameters. However, in reality, the same parameters
may be subjected to batch-to-batch variation, such as titer,
and it may also be possible to restructure parts of a process
(e.g., in a facility fit scenario) or even design a new process
(e.g., in a new facility design scenario). A sensitivity analy-
sis can help identifying parameters that need careful consid-
eration in such scenarios so as to deal better with
uncertainty, be it of environmental or economical nature.
Figure 6 shows the influence of changes in crucial process
parameters—including titer, capacity utilization,§ bioreactor
working volume, perfusion rate (VVD), pooling duration, and
perfusion run time—on water consumption (Figure 6a), solid
waste generation (Figure 6b), energy requirements (Figure 6c),
and COGS/g (Figure 6d) for a perfusion-based process. In gen-
eral (except for COGS/g), it can be seen from the figure that
the capacity utilization and pooling duration are the most influ-
ential variables with changes of 625% in either variable lead-
ing also to a change of around 625% on the output of three
impact categories. Varying the other process variables by
some degree leads to a change of around 5% in the different
impact categories. On the other hand, COGS/g is most sensi-
tive to variations in the titer, bioreactor working volume, and
VVD.¶ Note that while increasing VVD results in an increased
usage of media and thus increases the material and consumable
costs, the bioprocess model assumes that a higher VVD
increases also the (annual) throughput. In this particular set-
ting, relatively speaking, the throughput increased more signif-
icantly than the costs leading to lower COGS/g.
Note that the pooling duration is defined as the number of
days for which harvest is collected before further processing
and thus affects both the upstream and downstream setup. For
example, keeping the total production amount constant, a longer
pool duration (i.e., fewer upstream runs) leads to less frequent
purification runs and a larger downstream batch. The sensitivity
analysis shows that an increase in pool duration has a positive
effect on both the COGS/g and the environment. In fact, from
Figure 7 it can be seen that a pooling duration between 5 and
8 days and longer allow the perfusion-based process to be more
economical (achieved for pooling durations of 5 or more days)
and environmentally-friendly (achieved for pooling duration of
6 and more days) than the FB process (except for solid waste
generation as indicated in Figure 7c). Of course, if a longer pool
duration can be implemented depends strongly on the stability
of the protein and the downstream capabilities (e.g., equipment
and vessel size) of the process.
Finally, it is worth pointing out that water consumption
was more dependent on the frequency of cleaning operations
than the size of downstream equipment. Put simply, a down-
stream process with larger equipment but lower frequency of
cleaning operations consumed less water.
How sensitive is the environmental impact and COGS/g to
changes in the production scale?
The framework developed can be used to assess the envi-
ronmental impact and COGS/g of different production scales.
Figure 5. Impact of each waste treatment option on key envi-
ronmental metrics (a) water consumption, (b) energy
demand, (and c) CO2 emission. Basis in all cases is
28 kg-mAb/year.
§The capacity utilization is used to set the number of days in a year a facility
is run for, i.e., #operating days5 capacity utilization 3 365. In the base
case, the capacity utilization is set to 0.8 (or 80%).
¶In the case of a FB-based process, the parameters VVD, pooling duration,
and perfusion run time can be neglected. The impact of the other three varia-
bles, titre, capacity utilization, and the bioreactor working volume, on the
environment and the COG is very similar to impact observed for the
perfusion-based process.
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Figure 6. Results of sensitivity analysis showing impact of several process variables—perfusion run time, pooling duration, VVD, bio-
reactor working volume, capacity utilization, and titer—for a perfusion-based process on several environmental metrics—
(a) water consumption, (b) level of solid waste generation, (c) energy demand—, and (d) COGS/g. The process variables are
varied one at the time by 225% ( ) and 125% ( ). Basis in all cases is 28 kg-mAb/year.
Figure 7. Analysis of the impact of pool duration on (a) COGS, (b) water consumption, (c) solid waste generation, and (d) energy
requirements for a perfusion-based process ( ). The impact is measured relative to a perfusion process with a pool duration
of 4 days (hence the 0% change in metrics at pool durations of 4 days). As a reference, each plot shows the output of the
batch-based process ( ) (the straight horizontal line), which is independent of the pool duration and hence constant.
As an example, Figure 8 highlights the impact on (relative)
water consumption (Figure 8a) and COGS/g (Figure 8b) for
a FB and perfusion-based process for production scales rang-
ing from 28 to 1000 kg-mAb/year. It can be seen from Fig-
ure 8a that the distribution of the relative water consumption
changes significantly with the scale (the change was most
significant amongst the three impact categories considered,
water consumption, energy usage, solid waste generation). In
particular, the relative water consumption associated with the
chromatography units increased with the scale, while the
water consumption required for cleaning of buffer prepara-
tion/holding tanks decreased significantly. The former was
due to a rapid increase in the amount of buffer solutions
required to run a larger chromatography column (needed for
large production scales). The latter is due to the fact that the
increase in buffer solutions dominated the impact on water
consumption induced by larger equipment (tanks) needed for
buffer preparation/holding. When comparing the total water
consumption between the two processes for the different
scales, the perfusion process remained the more water-
demanding process consuming around 25% more than the
FB process (as observed previously in Table 4 and Figure 2
for a scale of 28 kg-mAb/year).**
Figure 8b demonstrates the impact of scale on the COGS/g
breakdown. It can be seen that the capital contribution is
becoming significantly lower as the scale increases, while the
contribution of materials and consumables increases. This
observation can be attributed to the economy of scales.
Conclusion
Economic factors are currently used to compare
manufacturing strategies in the biopharmaceutical industry.
While new developments are pushing this industry toward
greener manufacturing processes, only a very few environ-
mental studies have been conducted on the manufacture of
biopharmaceuticals. This study studied the use of a simulation
tool to assist in performing an LCA study. The use of a com-
mercial software tool, BioSolve, enabled this study to be com-
pleted within a reasonable timeframe. The ability to evaluate
quickly the environmental impacts from the simulation results
allows a decision-maker to weigh economic and environmen-
tal factors simultaneously at the process design stage.
Under the assumptions used and based on a 28 kg/year
output of a mAb, the perfusion-based process generated larg-
er environmental impacts compared with the FB process due
to more frequent cleaning of the downstream stage when the
pool duration was 4 days. However, both processes had simi-
lar water and energy consumption levels when the pool dura-
tion was increased to 8 days. The study also found that
water consumption greatly affected energy requirements as
Figure 8. Comparison of the (a) relative water consumption and (b) COGS breakdown of a FB (left bar for each scale) and perfusion-
based process (right bar for each scale) for production scales ranging from 28 to 1000 kg/year.
**The contribution of the centrifugation step (which was used by the FB-
based process only) to the water consumption was around 5% at each scale.
A similar contribution was observed for the energy requirement.
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energy was used in water production and liquid waste treat-
ment. CIP and SIP systems were identified as steps with
major environmental impacts.
Since water consumption influences energy requirements
and CO2 emission levels, and a significant proportion of
water was consumed in cleaning operations, the shift to
single-use equipment and a fully continuous mAb process
may be expected to reduce the environmental impacts.
The environmental impacts from three waste management
scenarios were evaluated. Arguably, the incineration process
was the most desirable option as it converted waste effec-
tively into energy, but at the expense of emitting more CO2.
The solid wastes generated comprised mostly non-degradable
plastics which are not ideal for landfill.
The study revealed also the impact on the economics of a
process is different from the environmental impact. For
example, while increasing the facility capacity increases
water and energy consumption, it can have a positive impact
on the cost of goods due to economics of scale.
Future studies could focus on comparing single-use with tra-
ditional bioprocess systems. Here, the system boundary must
be expanded to examine the whole life-cycle which also
includes equipment fabrication and consumables manufacture
in the supply-chain phase and equipment disposal in the end-
of-life phase. Further studies could include other environmental
impact criteria of interests such as acidification, global warm-
ing potential and aquatic toxicity. Finally, in addition to quan-
tifying the direct environmental impact of a plant as done in
this study, it would also be interesting to investigate the indi-
rect impact of a plant, which would depend on factors such as
the location of the plant, local regulations and logistics.
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Appendix A: Functional Unit Calculation
The following assumptions were made:
1. The monoclonal antibody is Avastin.
2. In 2011, there were 141,000 patients with lung cancer in
the United Kingdom.52
3. Only 80–85% of lung cancer patients have non-small cell
lung cancer.53
4. Approximately 75% of patients of non-small cell lung
cancer have non-squamous non-small cell lung cancer.
5. Only 40 % of non-squamous non-small cell lung cancer
patients are in the stage that can be treated by Avastin.
6. Five percent market penetration capacity of Avastin for
treating lung cancer patients in the United Kingdom.
7. Assume a dose size of 15.5 g per person per year.
Amount of mAb required5 141,000 3 0.85 3 0.75 3 0.4 3
0.05 3 15.55 27,865 mg per year  28 kg per year.
Appendix B: Parameters for a FB and Perfusion-Based Manufacturing Process
Unit Operation Parameter Setting Unit Operation Parameter Setting
Seed bioreactors Virus inactivation
Batch split ratio 1 Operational yield 100%
Batch pooling ratio 1 Base vol 0.50%
FB bioreactor Acid vol 1.50%
Titer (g/mL) 2 Anion chromatography
Working volume 45 Operational yield 89%
Operational yield 100% Capacity (g/L) 30
Feed ratio in 10 Bed height (cm) 20
Perfusion Product CVs 3
Titer (g/mL) 2 Target cycles 1
Working volume 45 Max # reuses 50
Operational yield 100% Cation chromatography
Perfusion rate (VVD) 2 Operational Yield 98%
Total run time (days) 60 Capacity (g/L) 30
Initial growth phase (days) 5 Bed height (cm) 20
# Days media prep 1 Product CVs 3
Centrifugation Target cycles 1
Operational yield 95% Max # reuses 50
Centrate 85% Viral filtration
Duration (h) 4 Operational yield 98%
Depth Filtration Flux (LMH) 100
Operational yield 95% Duration (h) 4
Flux (LMH) 2 Ultrafiltration/diafiltration
Duration (h) 4 Operational Yield 98%
Protein A chromatography Flux (LMH) 50
Operational yield 97% Duration (h) 4
Capacity (g/L) 30 Concentration factor 10
Bed height (cm) 20 Diavolumes 8
Product CVs 3 Max # reuses 10
Target cycles 4 Sterile filtration
Max # reuses 200 Operational yield 98%
Flux (LMH) 200
Duration (h) 2
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Appendix C: Basis of Calculation for Energy Balance
Manuscript received Mar. 15, 2016, and revision received June 28,
2016.
Table C1. Energy consumption of the production facility
Item Energy Required Source/Comment
PW and CIP production 558 (kJ/L) Ref. 46
SIP production 797 (J/s-L) Energy to heat water from 258C to 2508C
Filtration 50 (J/s-m2) Ref. 47
Media and buffer preparation 69.0 (J/s-L) Ref. 48
Liquid waste treatment (heat to 808C) 639 (J/s-kg-water) Inactivation of mammalian cells at 858C49
Lighting 15 (J/s-m2) Ref. 50
Table C2. Energy consumption of the unit operations
Item Working Volume Energy (J/s) Equipment Example
Bioreactor 50 mL to 5 L 126 WAVE Bioreactor 2/10
100 mL to 25 L 630 WAVE Bioreactor System 20/50
25 L 900 ReadyToProcess WAVE 25
10 L to 100 L 7200 WAVE BioreactorTM 200 system
500 L 12000 WAVE Bioreactor System 500/1000
Ion chromatography 1.5 mL/min 240 Cecil IonQuest Ion Chromatography System
7.5–510 L/h 600 €AKTA ready
up to 2000 L/h 1700 Bio-Rad InPlace Columns Product Information
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